Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections

Abstract

References

Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results

Rifampicin in treatment of experimental tuberculosis in mice

Rifampicin

A pilot trial of rifampicin in tuberculosis

Addendum on serum levels

Citations

A comparison of rifampicin, ethambutol or PAS in short-term monotherapy in pretreated cavitary pulmonary tuberculosis

Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis

Treatment of drug-resistant tuberculosis

"Rifampin--now that the secret is out"

"Control of tuberculosis" up-to-date

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

Multidrug-resistant tuberculosis in patients without HIV infection

Tuberculosis, drug resistance, and the history of modern medicine

In-vitro activity of erythromycin against atypical mycobacteria

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

Inhibitors of viral nucleic acid transcriptases

The rpoB gene of Mycobacterium tuberculosis.

Immunological responsiveness of tuberculosis patients receiving rifampin.

In vitro inhibition of Coccidioides immitis strains with amphotericin B plus rifampin.

Effect of rifampicin on liver function in man

Studies in venereal disease. I. Isolation of L-phase organisms of N. gonorrhoeae from patients with gonorrhoea

Mutation of gonococci and meningococci in vitro to rifampin (rifampicin) resistance

Effect of rifampicin on Proteus keratitis

Resistance to rifampicin: a review

Inhibition of mycobacterial growth by plumbagin derivatives

Nonclinical models for antituberculosis drug development: a landscape analysis

Rifampin in initial treatment of advanced pulmonary tuberculosis

Moving Beyond Directly Observed Therapy for Tuberculosis

Molecular imaging of bacterial infections: Overcoming the barriers to clinical translation

Adsorption of Candida albicans from blood of infected rats by coated charcoal. A model for the diagnosis of septicaemia

Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application

Initial treatment of tuberculosis with rifampicin.

On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex.

In vitro susceptibility of atypical mycobacteria to rifampin.

1H, 13C, 15N backbone and side-chain NMR assignments of the C-terminal domain of Mycobacterium Tuberculosis ribosome maturation factor RimM.

Newer antibiotics

Rifamycin antibiotics and the mechanisms of their failure.

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular Agents (ASM)

Allergy & Infectious Diseases (ASM)

Antimicrobial Resistance (ASM)

Allergy & Infectious Diseases

Antimicrobial Resistance

Related Papers

A 'single dose' treatment of gonococcal urethritis with rifampicin

Treatment of acute gonorrhoea with a single oral dose of rifampicin

Rifampicin in the treatment of chronic and polyresistant tuberculosis

Rifampin: its role in the treatment of tuberculosis

New drugs against tuberculosis